THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents
| Autor: | Greiner, Jeanette, Schrappe, Martin, Lassay, Elisabeth, Vorwerk, Peter, Lauten, Melchior, Sauerbrey, Axel, Rischewski, Johannes, Beilken, Andreas, Henze, Günter, Korte, Wolfgang, Möricke, Anja, THROMBOTECT Study Investigators†, Claviez, Alexander, Zimmermann, Martin, Niemeyer, Charlotte, Kolb, Reinhard, Eberl, Wolfgang, Berthold, Frank, Bergsträsser, Eva, Gnekow, Astrid |
|---|---|
| Přispěvatelé: | University of Zurich, Greiner, Jeanette |
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
medicine.medical_specialty Adolescent medicine.drug_class 2720 Hematology Low molecular weight heparin 610 Medicine & health Antithrombins Article 03 medical and health sciences 0302 clinical medicine Thromboembolism Internal medicine hemic and lymphatic diseases Antithrombotic medicine Humans Prospective Studies ddc:610 Prospective cohort study Child Childhood Acute Lymphoblastic Leukemia business.industry Heparin Antithrombin Infant Induction chemotherapy Anticoagulants Induction Chemotherapy Hematology Venous Thromboembolism Heparin Low-Molecular-Weight Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Acute Lymphoblastic Leukemia Leukemia Editorial 10036 Medical Clinic Child Preschool Female business 030215 immunology medicine.drug |
| Zdroj: | Haematologica Haematologica : journal of the European Hematology Association 104(4), 756-765 (2019). doi:10.3324/haematol.2018.194175 |
| ISSN: | 1592-8721 0390-6078 |
| DOI: | 10.3324/haematol.2018.194175 |
| Popis: | Thromboembolism is a serious complication of induction therapy for childhood acute lymphoblastic leukemia. We prospectively compared the efficacy and safety of antithrombotic interventions in the consecutive leukemia trials ALL-BFM 2000 and AIEOP-BFM ALL 2009. Patients with newly diagnosed acute lymphoblastic leukemia (n=949, age 1 to 18 years) were randomized to receive low-dose unfractionated heparin, prophylactic low molecular weight heparin (enoxaparin) or activity-adapted antithrombin throughout induction therapy. The primary objective of the study was to determine whether enoxaparin or antithrombin reduces the incidence of thromboembolism as compared to unfractionated heparin. The principal safety outcome was hemorrhage; leukemia outcome was a secondary endpoint. Thromboembolism occurred in 42 patients (4.4%). Patients assigned to unfractionated heparin had a higher risk of thromboembolism (8.0%) compared with those randomized to enoxaparin (3.5%; P=0.011) or antithrombin (1.9%; P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|